[{"id":"297a77ed-786b-4888-ac1d-20e877632775","acronym":"Renaissance","url":"https://clinicaltrials.gov/study/NCT05076682","created_at":"2021-10-13T16:58:20.229Z","updated_at":"2024-07-02T16:36:03.106Z","phase":"Phase 2","brief_title":"Reverse Triple Negative Immune Resistant Breast Cancer","source_id_and_acronym":"NCT05076682 - Renaissance","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ZNF689","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2 • ZNF689"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • efavirenz"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2022-10-03"}]